Abstract
Symptoms caused by acute human parvovirus B19 (HPV-B19) infection can vary considerably, from asymptomatic to severely symptomatic. A 39-year-old Japanese woman complained of sudden, severe arthralgia with edematous limbs coincident with an outbreak of HPV-B19 infection at the elementary school attended by her daughter. A diagnosis of acute HPV-B19 infection was made by the detection of serum antibody to HPV-B19 IgM and HPV-B19 DNA. Magnetic resonance imaging revealed bilateral synovitis of the cubital joints. The patient was immunocompetent and suffered from severe arthralgia associated with persistent HPV-B19 viremia for more than 4 months after the diagnosis of acute HPV-B19 infection. The administration of high-dose intravenous immunoglobulin resulted in remission, with little change in the serum HPV-B19 DNA level. Even in our immunocompetent patient, severe and prolonged arthritis was found to be associated with persistent viremia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chorba T, Coccia P, Holman RC, Tattersall P, Anderson LJ, Sudman J, et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis 1986;154:383–393.
Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004;350:586–597.
Franssila R, Hedman K. Infection and musculoskeletal conditions: Viral causes of arthritis. Best Pract Res Clin Rheumatol 2006;20:1139–1157.
White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR, Bacon PA. Human parvovirus arthropathy. Lancet 1985;1:419–421.
Mouthon L, Guillevin L, Tellier Z. Intravenous immunoglobulins in autoimmune-or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev 2005;4:264–269.
Stahl HD, Pfeiffer R, Emmrich F. Intravenous treatment with immunoglobulins may improve chronic undifferentiated monoand oligoarthritis. Clin Exp Rheumatol 2000;18:515–517.
Viguier M, Guillevin L, Laroche L. Treatment of parvovirus B19-associated polyarteritis nodosa with intravenous immune globulin. N Engl J Med 2001;344:1481–1482.
Lehmann HW, Plentz A, Von Landenberg P, Müller-Godeffroy E, Modrow S. Intravenous immunoglobulin treatment of four patients with juvenile polyarticular arthritis associated with persistent parvovirus B19 infection and antiphospholipid antibodies. Arthritis Res Ther 2004;6:R1–R6.
Centers for Disease Control and Prevention. Current trends risks associated with human parvovirus B19 infection. Morb Mortal Wkly Rep 1989;38:81–88, 93–7.
Kerr JR, Cunniffe VS, Kelleher P, Bernstein RM, Bruce IN. Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome. Clin Infect Dis 2003;36:e100–e106.
Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, et al. Experimental parvovirus infection in humans. J Infect Dis 1985;152:257–265.
Potter CG, Potter AC, Hatton CS, Chapel HM, Anderson MJ, Pattison JR, et al. Variation of erythroid and myeloid precursors in the marrow and peripheral blood of volunteer subjects infected with human parvovirus (B19). J Clin Invest 1987;79:1486–1492.
Patou G, Pillay D, Myint S, Pattison J. Characterization of a nested polymerase chain reaction assay for detection of parvovirus B19. J Clin Microbiol 1993;31:540–546.
Cassinotti P, Burtonboy G, Fopp M, Siegl G. Evidence for persistence of human parvovirus B19 DNA in bone marrow. J Med Virol 1997;53:229–232.
Söderlund M, von Essen R, Haapasaari J, Kiistala U, Kiviluoto O, Hedman K. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997;349:1063–1065.
Wong S, Young NS, Brown KE. Prevalence of parvovirus B19 in liver tissue: no association with fulminant hepatitis or hepatitisassociated aplastic anemia. J Infect Dis 2003;187:1581–1586.
Söderlund-Venermo M, Hokynar K, Nieminen J, Rautakorpi H, Hedman K. Persistence of human parvovirus B19 in human tissues. Pathol Biol (Paris) 2002;50:307–316.
Kurtzman GJ, Cohen BJ, Field AM, Oseas R, Blaese RM, Young NS. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 1989;84:1114–1123.
Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red cell aplasia of 10 years duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989;321:519–523.
Tyndall A, Jelk W, Hirsch HH. Parvovirus B19 and erosive polyarthritis. Lancet 1994;343:480–481.
Speyer I, Breedveld FC, Dijkmans BA. Human parvovirus B19 infection is not followed by inflammatory joint disease during long time follow-up. A retrospective study of 54 patients. Clin Exp Rheumatol 1998;16:576–578.
Munakata Y, Saito-Ito T, Kumura-Ishii K, Huang J, Kodera T, Ishii T, et al. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 2005;106:3449–3456.
Loizou S, Cazabon JK, Walport MJ, Tait D, So AK. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum 1997;40:103–108.
Lunardi C, Tiso M, Borgato L, Nanni L, Millo R, De Sandre G, et al. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol 1998;28:936–948.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Ogawa, E., Otaguro, S., Murata, M. et al. Intravenous immunoglobulin therapy for severe arthritis associated with human parvovirus B19 infection. J Infect Chemother 14, 377–382 (2008). https://doi.org/10.1007/s10156-008-0636-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10156-008-0636-x